Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Yi-Jiun Su; Anne Marijn Kramer; Mark P Hamilton; Neha Agarwal; Hrishikesh K Srinagesh; John H Baird; Bita Sahaf; Adam Kuo; Zachary J Ehlinger; Moksha H Desai; Skyler P Rietberg; Ramya Tunuguntla; Shabnum Patel; Harshini Chinnasamy; Nikolaos Gkitsas-Long; Dorota D Klysz; Annie Kathleen Brown; Sushma Bharadwaj; Saurabh Dahiya; Melody Smith; Lori Muffly; Crystal L Mackall; Zinaida Good; Steven A Feldman; David B Miklos; Matthew J Frank

doi:10.1158/2159-8290.CD-24-1071

Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL

Cancer Discov. 2025 Apr 2;15(4):733-747. doi: 10.1158/2159-8290.CD-24-1071.

Authors

Yi-Jiun Su^{1

2}, Anne Marijn Kramer¹, Mark P Hamilton^{1

3}, Neha Agarwal^{1

3}, Hrishikesh K Srinagesh¹, John H Baird⁴, Bita Sahaf^{3

5}, Adam Kuo^{3

5}, Zachary J Ehlinger^{3

5}, Moksha H Desai^{3

5}, Skyler P Rietberg^{3

5}, Ramya Tunuguntla³, Shabnum Patel³, Harshini Chinnasamy³, Nikolaos Gkitsas-Long³, Dorota D Klysz³, Annie Kathleen Brown³, Sushma Bharadwaj^{1

3}, Saurabh Dahiya^{1

3}, Melody Smith^{1

3}, Lori Muffly^{1

3}, Crystal L Mackall^{1

3

6

7}, Zinaida Good^{3

7

8}, Steven A Feldman³, David B Miklos^{1

3}, Matthew J Frank^{1

3}

Affiliations

¹ Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.
² Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
³ Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California.
⁴ Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
⁵ Cancer Correlative Science Unit, Center for Cancer Cell Therapy, Stanford University, Palo Alto, California.
⁶ Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
⁷ Parker Institute for Cancer Immunotherapy, San Francisco, California.
⁸ Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California.

PMID: 39775812
PMCID: PMC11964843 (available on 2025-10-02)
DOI: 10.1158/2159-8290.CD-24-1071

Abstract

Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

MeSH terms

Aged
Antigens, CD19* / immunology
Female
Humans
Immunotherapy, Adoptive* / methods
Leukapheresis
Leukemia, Lymphocytic, Chronic, B-Cell* / immunology
Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
Male
Middle Aged
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen* / immunology
Sialic Acid Binding Ig-like Lectin 2* / antagonists & inhibitors
Sialic Acid Binding Ig-like Lectin 2* / immunology
Treatment Outcome

Substances

Antigens, CD19
Receptors, Chimeric Antigen
Sialic Acid Binding Ig-like Lectin 2
CD22 protein, human
Receptors, Antigen, T-Cell
CD19 molecule, human

Abstract

MeSH terms

Substances

Grants and funding